Ocugen announced positive 12-month data from its OCU410 Phase 2 trial showing significant reduction in lesion growth for geographic atrophy, supporting a Phase 3 trial planned for late 2026. The company completed enrollment for key trials in retinitis pigmentosa and Stargardt disease, aiming for Biologics License Application submissions by 2027. Ocugen also priced a $115 million convertible senior notes offering, expected to extend its cash runway into 2028 after retiring higher-interest debt. These developments position Ocugen for potential regulatory approvals and commercialization of its gene therapies targeting blindness diseases.
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
